Member Info for BuenaVista

Well 200p gives a MCap of around $885m - for all Avacta's assets. That's a rubbish amount for what Avacta has. The BoD would never recommend that to the shareholders.

Would the board accept a 90p, 150p or even 200p offer? Wouldn't they want to hear what other companies might want to offer?

Or massive profits from Dx announced in this year's preliminary results - positive for the balance sheet going forward or for the sale value of Dx. Prelims surely due soon.

Was it planned that we only get the chance to pose questions when we registered and that that was pre-AACR and pre-DX being hidden away on the website?

Turner Pope - the institution Avacta (TG?) engaged for the fund raise that went around the City companies saying "Avacta are desperate for money. What's the minimum price you'll pay to buy shares?"

So what if the share price hasn't caught up with the reality yet? That just extends the buying opportunity for those that can see where AVA6000, pre|CISION and Avacta are headed.

But I'll feel a lot better about it after AS has given his talk and Q&A and I see where the SP has tanked to..

"The results confirm the positive progress being made in the clinical testing of AVA6000 and support the company’s above target fundraise of £31.1m completed in March which will fund the dose expansion and Phase 2 efficacy studies for AVA6000 as well as progress the company’s drug pipeline more generally, including its AVA3996 asset.

"If Phase 2 testing enables commercial sales to start from 2026/27, we calculate a value for AVA6000 alone at 89p rising to 182p on the implementation of Phase 2 testing."

https://www.capitalaccessgroup.co.uk/research-portal?#/portal/capital-access-group/research/23_2024041003302218579/referrer/GB00BYYW9G87

"...we calculate a value for AVA6000 alone at 89p rising to 182p on the implementation of Phase 2 testing." Just think on that.

I'll tell you what. It's a new day so let's forget about Avacta's RNS and make the BB all about the endless windbag that is wyndrum instead. Good idea! Morons.

Just ignore or filter this sad troll that for reasons best known to itself and its paymaster hangs around this BB every day. 🤷🏻‍♂️

Just ignore or filter this sad troll that for reasons best known to itself and its paymaster hangs around this BB every day. 🤷🏻‍♂️

"Avacta has two divisions: an clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division focused on supporting healthcare professionals."

Yes. AKA an Therapeutics Division and an Diagnostics Division. 😂😂😂

True, but even so...

Such a pity Avacta didn't tap PIs to progress AVA3996 to the clinic already, as originally planned.

I love it when you talk firty fella.

Aww. Are you missing your convo buddies?

@StarBright & Kingsley, Here's some homework for you - watch and listen to the CC presentation.

I don't think this RNS will do much for the share price short term given the mentality of AIM and the London market - probably a spike - but does a lot for the company's, and hence the share price's, long term prospects.

@Harrogate4, It's an Alan joke.

@Kingsley, Nice, maybe you'll meet sheppy there in the mirror.

"Even Alan can't feck this up tomorrow night."

SP 100p by 4:30 tomorrow, open 50p Thursday.

@CTSFO , route is pivotal Phase 2, provisonal regulatory approval and marketting, Phase 3 to check(finally prove) that it works. If Phase 3 were to fail, marketting approval would be revoked.

60-year-old male patient with a right-side popliteal mass biopsy diagnosed with a grade 3 undifferentiated pleomorphic sarcoma (UPS). Prior cancer therapy preoperative radiotherapy (May-Jul 2021) followed by surgery (Sept 2021, viable tumour cells in less than 10% of tumor volume). Stage IV diagnosis (March 2022) with pleural metastases, enrolled in etigilimab + nivolimab (clinical trial June 2022-Jan 2023) with disease progression prior to enrolling in the AVA6000 phase 1 trial

Moral of the story: Never give up hope

Case Study:

60-year-old male patient with a right-side popliteal mass biopsy diagnosed with a grade 3 undifferentiated pleomorphic sarcoma (UPS). Prior cancer therapy preoperative radiotherapy (May-Jul 2021) followed by surgery (Sept 2021, viable tumour cells in